CYP2C19 Phenotype, P2Y12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy.

Saved in:
Bibliographic Details
Title: CYP2C19 Phenotype, P2Y12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy.
Authors: Patel RC; Division of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA., Thomas CD; Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy University of Florida Gainesville FL USA., Rossi JS; Division of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA., Franchi F; Division of Cardiology, Department of Medicine, College of Medicine-Jacksonville University of Florida Jacksonville FL USA., Keeley EC; Division of Cardiovascular Medicine, College of Medicine University of Florida Gainesville FL USA., Beitelshees AL; Department of Medicine and Program for Personalized and Genomic Medicine University of Maryland School of Medicine Baltimore MD USA., Duarte JD; Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy University of Florida Gainesville FL USA., Ortega-Paz L; Division of Cardiology, Department of Medicine, College of Medicine-Jacksonville University of Florida Jacksonville FL USA., Kulick N; Division of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA., Winget M; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC USA., Nguyen AB; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC USA., Yang WE; Department of Medicine and Program for Personalized and Genomic Medicine University of Maryland School of Medicine Baltimore MD USA., Venkatesh S; Division of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA., Angiolillo DJ; Division of Cardiology, Department of Medicine, College of Medicine-Jacksonville University of Florida Jacksonville FL USA., Cavallari LH; Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy University of Florida Gainesville FL USA., Lee CR; Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC USA., Stouffer GA; Division of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA.
Source: Journal of the American Heart Association [J Am Heart Assoc] 2025 Jul 15; Vol. 14 (14), pp. e041634. Date of Electronic Publication: 2025 Jul 03.
Publication Type: Journal Article; Multicenter Study
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 101580524 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2047-9980 (Electronic) Linking ISSN: 20479980 NLM ISO Abbreviation: J Am Heart Assoc Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2047-9980
DOI:10.1161/JAHA.125.041634